Orphan Therapeutics Accelerator (OTXL) has in-licensed an investigational therapy program for ornithine transcarbamylase deficiency (OTCD), a rare metabolic disorder. The therapy, now named OTXL-101, was previously known as AAVLK03hOTC and developed through collaborations at University College London and Children’s Medical Research Institute.
This marks OTXL’s first in-licensed therapy. The nonprofit biotech aims to revitalize shelved therapies for rare conditions. OTXL is part of a broader strategy that includes a network of contract development and manufacturing organizations and a commercial subsidiary for product availability.
OTXL-101 utilizes a liver-targeted adeno-associated virus vector to deliver a functional OTC gene. It has received orphan drug designations from the U.S. and EU. Initial evidence suggests potential benefits for patients, as one treated patient improved significantly and was taken off certain medications.
OTXL is also exploring additional candidates for in-licensing, indicating a flexible approach to various treatment modalities beyond gene therapies.
Source: genengnews.com · Image: Bio Threats- FDA's A-Team (6355) (9806964753) by The U.S. Food and Drug Administration, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
